Renk C M, Gupta R K, Irie R F, Morton D L
J Surg Oncol. 1982 Mar;19(3):155-61. doi: 10.1002/jso.2930190309.
The humoral immune response to tumor-associated antigens (TAA) in cancer patients undergoing immunotherapy can vary considerably. This variability is inherent from patient to patient and is also dependent on the type of assay used to measure patient antibody response to tumors. In this investigation four serological techniques, complement-dependent antibody-mediated cytotoxicity, immune adherence, complement fixation, and indirect membrane immunofluorescence, were used to assess the humoral immune response in melanoma patients receiving specific immunization with cultured allogeneic melanoma cell vaccine. Two different patterns of antibody response were elicited. One was directed against TAA and oncofetal antigens (OFA) and the other was against HLA antigens. The sensitivity and reactivity varied among the different techniques suggesting that one test or technique may not be sufficient to evaluate critically a patient's response to immunotherapy.
接受免疫治疗的癌症患者对肿瘤相关抗原（TAA）的体液免疫反应可能有很大差异。这种变异性在患者之间是固有的，并且还取决于用于测量患者对肿瘤抗体反应的检测方法类型。在这项研究中，使用了四种血清学技术，即补体依赖性抗体介导的细胞毒性、免疫黏附、补体结合和间接膜免疫荧光，来评估接受培养的同种异体黑色素瘤细胞疫苗特异性免疫的黑色素瘤患者的体液免疫反应。引发了两种不同的抗体反应模式。一种针对TAA和癌胚抗原（OFA），另一种针对HLA抗原。不同技术之间的敏感性和反应性各不相同，这表明单一的检测或技术可能不足以严格评估患者对免疫治疗的反应。
